

AD _____

Award Number: DAMD17-01-1-0241

TITLE: Discovery of Novel Mammary Developmental and Cancer Genes Using ENU Mutagenesis

PRINCIPAL INVESTIGATOR: Christopher Ormandy, Ph.D.

CONTRACTING ORGANIZATION: Garvan Institute of Medical Research
Darlinghurst, NSW 2010,

REPORT DATE: September 2005

TYPE OF REPORT: Final

20060213 033

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-09-2005		2. REPORT TYPE Final		3. DATES COVERED 1 Oct 2001 –29 Aug 2005	
4. TITLE AND SUBTITLE Discovery of Novel Mammary Developmental and Cancer Genes Using ENU Mutagenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-01-1-0241	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Christopher Ormandy, Ph.D.				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Garvan Institute of Medical Research Darlinghurst, NSW 2010, Australia				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This project sought to discover new genes involved in mammary gland carcinogenesis using ENU mutagenesis. The initial approach involved screening ENU mutagenised mice for mammary tumors. Screening of 1100 mice by mammary whole mount histology identified a number of pedigrees with mammary tumours attributable to ENU-induced recessive mutation. We failed in all cases to recapitulate the original phenotype in subsequent rounds of breeding, indicating the influence of environmental mutagenic events in this initial screen. In our second attempt we are screening for reduced latency to palpable mammary tumors in response to expression of a doxycycline-inducible myc oncogene, that is produced by the loss of a second gene knocked out by random ENU mutagenesis. This screen is currently underway. A number of factors have slowed the progress of this project. Firstly the unexpected failure of the first screen forced a change in strategy. The new strategy, employing oncogene sensitization, required the import of a mouse model from the USA. Stringent animal house regulations in Sydney and Canberra forced this line to be rederived twice by embryo transplantation. The failure of the first round caused the loss of our space in the ENU facility, and new space only became available following the construction of a new ENU facility in Canberra. Despite these set backs we are continuing with the project using funds obtained from the Australian NH&MRC, and hope to discover new oncogenes cooperating with myc during carcinogenesis.					
15. SUBJECT TERMS Breast Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	22	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover

SF 298

Table of Contents 1

Introduction 2

Body 2

Key Research Accomplishments 9

Reportable Outcomes 10

Conclusions 11

Appendices 12

Introduction

To date there has been no systematic search for genes controlling mammary development and carcinogenesis, and this project seeks to undertake the first such search by participation in the large scale ENU mutagenesis project currently being conducted at the John Curtin School, Australian National University (ANU), Canberra.

Body

Functional characterization of genetic loci is urgently required if the completion of the mouse genome is to be of immediate benefit. This requirement is being met in a number of ways, including a number of large scale ENU mutagenesis projects under way worldwide. Of these, just three are undertaking genome wide recessive screens. Recessive mutations, requiring the loss of function of two alleles, provide far greater insight into the genetic control of normal development and carcinogenesis than dominant, gain-of-function mutations, but require more complex breeding of pedigrees. This has been achieved at the ANU, where the established program of ENU mutagenesis has recently received significant financial support from the Australian Federal Government (\$A11.5 million Major National Research Facilities Grant) and The Australian National University (\$A8 million) for the construction of expanded animal handling facilities. This facility is now operational and has been further supported by an \$8 million Enabling Grant from the National Health and Medical Research Council. Our participation in the application for these grants, made possible by funding from the US Army BCRP for ENU mutagenesis projects at the ANU, provided multi-Institutional support for the proposals that was crucial for their success.

We adopted this technology early in its evolution at the ANU and screened the pedigrees that were produced by the first round of mutagenesis. Screening was undertaken using whole mount histology of the 4th inguinal mammary gland. Approximately 1100 mice were analyzed, and a number of abnormalities and tumors were identified. From these 6 pedigrees were selected

for propagation. Male siblings of affected females from these 6 selected pedigrees were used to recreate the pedigrees using a 3 generation inbreeding scheme. Members of these pedigrees were tested by mammary biopsy to identify affected individuals that could then be used to establish stable breeding lines and begin the mapping crosses. As detailed in our first annual report this strategy failed as we were unable to reproduce tumors at the frequency at which they were first detected. As a result of the failure of this first attempt we lost our animal holding space within the ANU facility to competing ENU mutagenesis projects. Consequentially we were forced to wait for the construction of the new facility to continue, and in this time we investigated alternative approaches that we could take.

We believe that our failure to reproduce the tumor phenotypes detected in the original screen was due to the multiple mutations required for tumor formation. In the original screen the ENU provided a sensitizing mutation, and the environment the subsequent mutations required for tumorigenesis. By definition these subsequent hits occurred within a short time frame to allow the detection of tumors at 8 months. When we attempted to recapitulate these pedigrees we believe that although the ENU mutation was present, the other hits did not occur within the time frame allowed by the necessity to breed from affected animals.

We had expected that a single mutation provided by ENU would provide sufficient sensitization to tumor formation for success, but the experiment has shown us otherwise. This failure has led us to redesign our methodology to include a sensitizing event in the background, allowing ENU to provide a second hit. We believe that introduction of a transgenic oncogene into the background will enable ENU to provide a second hit in the carcinogenic process. We believe, based on the proven enhancement of carcinogenesis by combined oncogenes (such as myc and ras), that this approach will allow us to regenerate pedigrees with enhanced tumorigenesis due to the ENU-induced loss of tumor suppressor gene function.

In year one to two we investigated the constitutively active C3-SV40T transgenic model as a prototype transgenic model. The issue with such models was whether the pregnancy-induced decrease in tumor latency, which is seen in most mammary specific transgenic models due to the

sensitivity of the MMTV promoter to pregnancy hormones, would hamper successful breeding of our pedigrees. We examined 58 breeding pairs held at the Garvan Institute. Twelve (21%) females were unable to wean pups due to tumor burden following the first pregnancy. Of the 36 animals examined following a second pregnancy, 27 (75%) were unable to wean pups. Ethical considerations, of <10% tumor burden, generally precluded a third mating. This investigation demonstrated that constitutive transgene expression would greatly hamper the breeding of pedigrees and the mapping crosses, especially as we would expect tumor latency to decrease in the context of an ENU-induced loss of a tumor suppressor gene.

An inducible transgene system is required. Such a system was constructed in the laboratory of Dr Lewis Chodosh. It utilizes the MMTV promoter to drive the expression of the reverse tetracycline-dependent transactivator, resulting in mammary specific expression of the tet-operator controlled transgene in response to treatment with tetracyclin. This model is insensitive to the hormonal state of the animal and shows no tumorigenic activity in the absence of doxycycline. We know from our experience to date that a single ENU-induced mutation does not hamper the breeding of pedigrees, and so use of this system, where transgene activity is induced for screening, but remains off for animal propagation, offers us the best method of achieving our aims.

The transgene of choice would induce tumors with a latency of six months or more, allowing us to find animals harboring homozygous ENU induced mutations due to significantly decreased latency. The transgene should also have direct relevance to human breast cancer. Ideally, many of the tumors would regress once transgene expression was turned off. All these criteria are met by the tet-operator-myc bi-transgene model developed by the laboratory of Dr Lewis Chodosh.

We imported the two transgenic lines from the Laboratory of A/Prof Lewis Chodosh, and had them released from quarantine. The lines were rederived and placed behind the barrier of our SPF facility at the Garvan Institute. The colonies of each line were established and PCR based genotyping assays were established and verified. We commenced the three-stage intercross of

these lines to provide animals (TOM*/* MTB */ in the scheme below) suitable for breeding with ENU mutagenized animals.

The new ANU facility was completed on schedule mid in mid 2004, at which point commissioning began and it is now operational, see <http://www.apf.edu.au> for details. This new facility was unable to accept our animals until January 2005, and then required that they were rederived, despite their demonstrated SPF status, to comply with the instructions of their newly appointed Scientific Advisory Committee. The animals have now been rederived into the facility and our screen for mutations that enhance myc-induced oncogenesis is underway. This project will continue through 2006 with funding obtained from the Australian National Health and Medical Research Council. As a result of these delays we are a long way behind the SOW.

Although the scientific findings of this project are yet to be made, this project and our initial attempts have been viewed favorably by a number of independent grant review panels. We participated in two grants that have provided very significant funding for the construction of a new animal facility, and the banking of induced mutants. We have also obtained ongoing funding for the ENU-myc project. These grants are detailed below.

This project has great potential to discover genes that interact with myc during the carcinogenic process, and to thus provide insight into this process in human carcinogenesis.

Project outline

Abbreviations.

TOM = tet on Myc which is the myc oncogene driven by tet on promoter.

MTB = MMTV-rtTA which is the reverse tetracycline transactivator driven by mouse mammary tumour virus LTR. Mammary specific.

/ Homozygous transgenic animal

*/ Heterozygous transgenic animal

Production of animals suitable for breeding to ENU mutagenized males.

The tet inducible system is bitransgenic, requiring the intercross of the imported mice to produce animals suitable for breeding, as follows.

1. TOM*/* bred with MTB */ produces 50% TOM*/ , MTB*/
2. TOM*/ , MTB*/ bred with TOM*/* produces 25% TOM*/*, MTB*/
3. TOM*/*, MTB*/ bred with TOM*/* produces 50% TOM*/*, MTB*/ suitable for breeding with ENU mice.

Cross with ENU mice.

We will make two populations, a control population without ENU mutations to accurately establish the kinetics of tumour induction, and a test population to screen for ENU mutations which accelerate or prevent tumourigenesis in response to myc. We will test each for dominantly and recessively acting mutations

Control population

wt C57Bl6 male mated with FVB TOM*/* MTB */ female. Wt population- aim for 320 animals made from 20 pedigrees. These animals are generated first and establish the normal profile of tumour onset in response to induction of myc.

Test population

G1: G1 males produced by breeding ENU treated B6 males with normal B6 females. G1 Bl6 male mated with FVB TOM*/* MTB */ female (test group, begin 12 weeks after WT group begins). 16 animals per pedigree, 200 pedigrees.

Dominant screen

Breed and keep eight female G2 progeny that are TOM */ MTB */ =50% of females (requires average of 16 females to be bred and typed from each pedigree). All are F1 Bl6/FVB. Add doxycyclin/sucrose to drinking water at 6weeks. Observe characteristics of tumour onset in the wt population that is running 12 weeks ahead of the test group. Involves palpating mammary glands for tumours, recording onset, number, position etc.

Identify animals in the test group that show accelerated tumour onset (early tumors) or resistance to tumour onset (late or no tumours). Remove Dox from water and breed affected female with WT FVB male to begin mapping.

Recessive screen

Keep four male and four female G2 offspring from each pedigree for breeding to G3. Generate animals as above, for both wt and ENU populations but then intercross progeny to produce G3 females homozygous for mutations. An intercross of male and females that are het for both MTB and TOM results in the following animals

	wt	MTB*/	MTB*/*
wt	1/16	2/16	1/16
TOM*/	2/16	4/16	2/16
TOM*/*	1/16	2/16	1/16

So 4/16 of animals are the exact genotype but 9/16 have both TOM and MTB transgenes, but the MTB^{*/*} animals (3/16) will be poor breeders. How tumorigenesis will be effected by dosage of TOM and MTB is unknown. The system shows titratable expression with Dox, so with luck gene dosage will not dramatically effect tumour onset. It is possible to distinguish homozygotes from hemizygotes using quantitative PCR. We will need to test this as we go in the control group. We expect that a combination of F2 FVB/Bl6 and variable gene dosage will make tumor onset more variable, but dramatic phenotypes, such as no tumors, should remain detectable. Screen and map as for the dominant screen.

REVISED SOW 2003-2005

Task 1.

Months 1 to 9.

1. Establish Tet-myc bitransgenic mice at ANU by rederivation.
2. Establish genotyping PCRs and test.

Task 2. Establish and screen 200 inbred pedigrees

Months 9 to 18.

- a. Mate homozygous FVB Tet-myc bitransgenic females with 200 C57Bl6 ENU mutagenised males to establish 200 pedigrees. Keep G1 males. Simultaneously mate 20 unmutagenised males to establish 20 control pedigrees.
- b. Mate G1 males to homozygous Tet-myc bitransgenic females to produce G2 offspring.
- c. Mate G2 females with their fathers to produce 25 G3 females per ENU or control pedigree.
- d. Induce transgene expression at 9 weeks of age with doxycycline. Monitor G3 females for mammary tumors by palpitation every 10 days. Select females with tumors from the ENU group which become palpable before tumors are seen in the control group.

Task 3. Establish pedigrees from selected females.

Months 12-24

- a. Stop doxycycline treatment and mate tumor bearing female with father, or brother if father fails to breed. Test progeny for accelerated tumorigenesis and breed pedigree to homozygosity. Examine tumor phenotype to prioritize pedigrees for mapping.

Task 4. Map mutations

Months 24-36.

- a. Mate homozygous females to male FVB to produce F2
- b. Phenotype F2 and collect DNA into affected (20 animals) and unaffected (20+ animals) pools.
- c. Genotype using 100 micro satellite markers polymorphic between FVB and C57Bl6 chosen throughout the genome.
- d. Identify locus and regenotype using 100 locus specific polymorphic markers.
- e. Continue intercross/backcross if no informative recombinations are found.
- f. Identify candidate genes at a sub 1 cM locus from the mouse genome map. Exclude those not expressed in the mammary gland. Begin sequencing of remaining candidates to identify ENU-induced mutation.

Key research accomplishments

- Screening of 1100 mutagenised mice and the identification of a number of developmental abnormalities including tumorigenesis, providing a proof of principal example that ENU mutagenesis can be used to find recessive cancer causing mutations. Correlation of developmental abnormalities, such as increased side branching, with tumor formation.
- Demonstration that uncontrolled environmental factors contributed to tumour formation in the ENU pedigrees, demonstrating the requirement for a sensitizing mutation approach to this project.
- Investigation of the C3-SV40T transgenic line as potential sensitizing mutation, and rejection based on pregnancy driven carcinogenesis. This led to the use of an inducible system.
- Import, rederivation and release from quarantine of the bi-transgenic tet inducible myc model of mammary carcinogenesis. Two mouse lines were imported. The TOM*/* line and the MTB */* line.
- Development of a quantitative PCR genotyping approach to enable homozygote transgenic animals to be distinguished from heterozygote animals.
- Export of the TOM/MTB line to Canberra and its subsequent rederivation (again) into the Australian Phenomics Facility. Release from internal quarantine.
- Intercross of the the two lines for production of TOM*/* MTB */* animals for breeding to ENU mutagenized males.
- Production of the control population beginning July 2005 and the production of the ENU mutagenized pedigrees for screening, beginning August 2005.
- Monitoring of test pedigrees from September.

Reportable outcomes

Presentations regarding this ENU mutagenesis project.

2002 Australian Health Medical Research Congress, Melbourne.
2002 Era of Hope US Army Breast Cancer Conference
2004 Victorian Breast Cancer Research Consortium Melbourne
2005 Australian Phenomics Facility Opening Symposium

Grants referring to this ENU mutagenesis project.

NHMRC Enabling Grant \$1.5M over 5 years.

Title: NHMRC Australian Phenome Bank

CI: Chris Goodnow, David de Kretser, Moira O'Bryan

Assoc Investigators: Brandon Wainwright, Antony Basten, Chris Ormandy, Anthony D'Apice, Warren Alexander, Anthony Scalzo, David Pass

Grant to provide banking of ENU-induced mutant mice and other induced mutants.

Commonwealth MNRG Grant \$11.5 M.

Title: Australian Phenomics Facility

Participating Organisations: ANU, Dairy CRC, Monash Uni, The Garvan Institute, Institute of Molecular Bioscience

Grant to build the new ENU facility. This grant secured an additional \$8M from the ANU in matched funding and further funding from the ACT Government, providing the funds for the construction of the APF. See attached .pdf brochure for a description of the facility.

NHMRC Program \$5M over 5 years.

Title: Control of cell proliferation and differentiation in breast and prostate cancer

CI: Robert Sutherland, Roger Daly, Liz Musgrove, Chris Ormandy

Grant, part of which will provide continuing funding for this ENU project.

Salaried positions

Research Assistant for 4 years

Filled by 2002 Simon Junankar, 2003-2004 Micheal Kazlauskas, 2005 Daniel Gorman.

Animal Technician s at ANU. Rotating Roster of many people.

Conclusions

So What?

If we are successful we will discover new tumor suppressor genes that are active in the mammary gland, in the case of reduced latency mutations, or genes essential for myc-induced tumourigenesis, in the case of increased latent or tumor-free pedigrees. This will have direct relevance to breast cancer, providing potential markers of prognosis and new targets for therapy.

Appendices

1. APF Brochure



4 H E !AU ISATNR O H E N O M I C S & A (

W W A P F E D U A U



THE ITALIAN GOVERNMENT IN CONJUNCTION WITH THE CHATEAU
 !USATIAN .A TICINALE)NSTI VOEDITION AND \$PVEL OPMETIN
)NSTITU TE OF -OLECULAR "SIT0 SOF IIE EENSLANDTANZ MHE 'SRVIAWE I
 AN OPEN ACCESS -AJOHR&C. IAHTEIATOMA M TOREZOMISC'S A&C ILITY E ! 0
 FEET OF SPATRUECANI RDATA BASE SYSTEMS

THE !0 & IS ONES DEADING HF EC IWAO THINEAS D F NTES ER ANSAP TE DUNIALA TRI
 GENOME PHENOME CODE




(OW THE ^ GENES IN THE GENOME SEQUENTIAL THE OUFN IF
 CHARACTERISTICS AND FESSE UETS HANG FLOTCH EDET OBUUACTIVATIONST WERT H
 ESECR COMMUNITY

[Handwritten signature]

00PSSOR #HR ISETTRO BODNOW

00CESS OF 'E NOSICEOV B HENOME \$ I

!CCCESS POINTS EC AFERR ! 0 &



"IOLOG ISY SATLEOM INTER

\$EVELROB SPHENOTSCEE N

3CEEN . 5GENVARIANTEE S

3E LEA OETX PAP EID ECHRNTEE R

- ACPHORMO SOLINAKOFGUETAT IONS

&URTHPE RNOTCYHAETERISATI


)DENT IFCYANDIDA GENES

3EQUE NCCANDIDA GENES

)DENT IFNOVEL MUTATIONS

\$ISCOVENRE BIOLOG PIRCEASLS

\$) 3 # / 6 % 2 9 / 4 %) . 3 6 % . , \$) 0' 2 ! / 2 9 ! # # % 3 3
 ") / , / ' 14 # (! 9 3 9 03 # 2 % % .) . 3 7 ' ,) " 2 ! 2 9 # / . 3 4 2 5 # 4) /
 ' % . / - % 7) \$ % 6 ! 2) ! . 40 2 / * % 5 2 3 ,) " 2 ! 2) % 3



4 HEESEH RTEAM CONSTRENSC TAS ' E N
 VARIANTRY I N B PARATNI EQUUNORR S '
 TO ALLOW DEEP MINING OF PART I
 PHE NOMOJECTS OR RUN ON THE COND I
 FACILITS YCAN S OCHESSTNAGH HUSI B R
 4 H EEL L7COR MSE 4) MMU NOLOGY CH . O
 & OUNDATION . ERVOUS SYSTEM
 2 ESEHA ROUND ATION . (- 2 # \$ 1

% 8) 3 4) . ' ,) " 2 ! 2 9 # / 0 9) . '
 0 2 / * % # 4 3

4 HEESEH RTEAMENSS EIRARI NBST E U N
 PARTIAL COPIES ARDES TIOH EESMEA DEI
 OF THEE OFA THUR PHENO TYPEGE \$ UAN

' E NOME WIDE CHEMICAL MUT # 2 # E N A C T A S T I O N MOUSE
 SPERMATOGONIA WISENHR % 5 THA LL O W R
 A HIGATI O N R OF MAMMALIANED GENES TO BE ALTER
 WITHOUT ANY PRIOR ASSUMPTIONS ' O R ' K N O W L E D G E % .)
 ABOUT THEIR PHOMES I O G I S R O E I T C H A E S E R R A RTEAMENSS PHENO TYE S T E O F
 GENE VARIANT MICE CAN BE S EXA N T A G D E L S T I O C H I N T E R F E R A N Y R G E
 OF INST ENR A HALL E L H H A S H I O N A R \$ H O N S O R O E N T E Q U R R I N G C O P I E S Y O F
 MUTATI O N U S E D P B Y % . 5 G E A Y N E E I O L E G A ' A R V A R) N A S T ' H A T N U C T R E O S I S D R ,
 GENE VARIAN T A P I A N G L O E S S I D E S F U N - C O N A I S H N I S T N O I E V A E R O N T S E R T I L I I
 IN INDIV T E U M A D O M A I N S A N D S P L I C E V A R I A N T S
 PARTIAL FUNCTACUINSEI ONAS E T H A C V
 REVAL E N T F F E N C L E S O T H E A M E V A R R E
 BY COMPLETE A B O S E E I N D U C T R O F A

4 H E ! O D U C E S A R I E S I O R % . 5 G E N E
 MICE O N D I C E S T S E R R G E N E T I C A L L Y
 B A C O U N R D 4 S E S A R I E S I S P R E D C F T O U R R
 D E T E C T I O N E C C E S S I V N E E O R D E T M O N S A
 M A M M A L I A N P H Y S I O L O G I C A C I E S S E R
 4 H E P H E S E I A E R S I G N E D S O T H E O F F
 ' S T A O M E A N Y R O W E E D E R ' P A I R B W R I L
 A P O X R I M A T E L Y E C E S S A N M I O Z M E
 G E N E M U T A T I O N S W I T H E A C H A F
 F R E Q U E N C Y O F ! M I N I M U M
 F A M I L Y S E A R E D S O T H A T M U L T A G E L
 W I L L S H O W T H E A T S A E M S E U R P
 R E P O D U C I B I L I T Y I N E F F E H B I O S E N G P E H
 F O R F U R T H E R A N A L Y S I S



A L
 C H



\$ % 6 % , / 0 - % . 4 ! 1 4) \$ / .) / ! 8 0 # 1 5 % - 3 % 4) 4 / . 4) . / \$ // 2 ' 2 / " 5 3 4 4 9 0 0 X # . 3 / # 2 % % . 3 5 4) 0 , % 4 0 () % # ! . 3 % 4 3 5 3) 4 (% - 5 h 3 4 % 2 0 % ! 2 ! 3 %

DISCOVERY OF GENE VARIANT MICE WITH A PHENOTYP OF INST EDREPENEL SABLOE N C E S C E E R A N E N O T R E P E N S O N M H L T I P L E E S M O U E F I C I E N T A H C E R ! 0 & H A S E X P E R T A T E S G E A A M O U N T S O F D A T A F O R A C C E S S T O S T A T E O F T E E F I P M E N T M U S A E A T A C T I C I N E S D T O E A C H M S O F T E W F O R D E V E L O P I N G A N E N S I B E E N E M S E T N E T D I N G S C R M A M M A L I A N B O D Y S Y S T E M S A N D A N A L Y S I N G T H E E F F E C T S P E C I I C G A T N E N A L T E R

4 H E U S E R D A T A B A S E R U N N I N G O N M A I N T A I N S A N D M A E L A T I N G S I N S L S 4 H E ! O V E D E S K E Y T E C H N O L O G I E S A N D O I R D I V I D U A N M I T E N F E L D I N C L U D T H E F O R M O F N E T W O R K E D E Q U I A P N E G E N O T Y P E D A T A X P E R U L H T S S O G

S P A M E T E R m O W C Y T O M E T E R A N G E S S I O N L A N Y P O R T I N T H E W W S C L I N I C A L A U T O A N A L Y S E R M A N A G E M E N T T O O L S D E V E I N C A P L E A D B S P A T H O L O G Y H I S T O L O G Y S C E E S S E R O T H E F O R O J E C T S O A N B E T O P R S \$ 8 ! A N D A P H I O C M O E R G I N G O F F S I O T A M S P R

S I F F Y M E T R I X A N D O A A Y P G E N E S S E I D O X N M R C R P O I L I N G

S . E T W O R K O F S P E C I A L I S T S O N A N T E A C H O F T H E P R I N S T I T U T O Y I D N S P E C I A L I S E D E X P E R T I S E I N P H E N O T Y P I N G A N D E V A L U A T I N G C H A N G E S I N M O S T I M P O R T A N T B O D Y S Y S T E M S

4 H E U S E R E N C L U D E S

S 3 Y S T E M S T O L I N K S A M P L E S I N W E L L T H E S C R O M E T A N D D A T A O M N S A M P L E S

S ! U T O M A T E D T O O L

F A M I L E Y A N D R I N H E R I T A I D E E B o m W e a n e d U P T O F O U R O B S E R V A T I O N

S 6 I S U A L I Z A T A C K I N N A N D T R T O O L S I D O N A T E O A N D P L A N M U L T I P A L I E I E N A R R

S 2 E G I E D T O E O R U N I Q U E L Y

I D E N T I L E S T H E P L A T E A N D A L L T H E S A M P L E S O N T H E

The Monitor	Export	Set	Select	Find	Show	Next menu
Gallery Filter Reports 27204 (28-Sep-2004)						
Selected sample 01G:LowTh:Men ENCASTRAIN:001LOWTH:LOW MEMORY:1000000:1000000:G7						
Printed						
Litter # Born Weaned						
1	9604	Low				
2	12704	Low				
3	16904	19004	21			
4	18504	21904	22			
5	24304	26304	23			
6	28504	30504	24			
7	32704	34704	25			
8	36904	38904	26			
9	41104	43104	27			
10	45304	47304	28			
11	49504	51504	29			
12	53704	55704	30			
13	57904	59904	31			
14	62104	64104	32			
15	66304	68304	33			
16	70504	72504	34			
17	74704	76704	35			
18	78904	80904	36			
19	83104	85104	37			
20	87304	89304	38			
21	91504	93504	39			
22	95704	97704	40			
23	99904	101904	41			
24	104104	106104	42			
25	108304	110304	43			
26	112504	114504	44			
27	116704	118704	45			
28	120904	122904	46			
29	125104	127104	47			
30	129304	131304	48			
31	133504	135504	49			
32	137704	139704	50			
33	141904	143904	51			
34	146104	148104	52			
35	150304	152304	53			
36	154504	156504	54			
37	158704	160704	55			
38	162904	164904	56			
39	167104	169104	57			
40	171304	173304	58			
41	175504	177504	59			
42	179704	181704	60			
43	183904	185904	61			
44	188104	190104	62			
45	192304	194304	63			
46	196504	198504	64			
47	200704	202704	65			
48	204904	206904	66			
49	209104	211104	67			
50	213304	215304	68			
51	217504	219504	69			
52	221704	223704	70			
53	225904	227904	71			
54	230104	232104	72			
55	234304	236304	73			
56	238504	240504	74			
57	242704	244704	75			
58	246904	248904	76			
59	251104	253104	77			
60	255304	257304	78			
61	259504	261504	79			
62	263704	265704	80			
63	267904	269904	81			
64	272104	274104	82			
65	276304	278304	83			
66	280504	282504	84			
67	284704	286704	85			
68	288904	290904	86			
69	293104	295104	87			
70	297304	299304	88			
71	301504	303504	89			
72	305704	307704	90			
73	309904	311904	91			
74	314104	316104	92			
75	318304	320304	93			
76	322504	324504	94			
77	326704	328704	95			
78	330904	332904	96			
79	335104	337104	97			
80	339304	341304	98			
81	343504	345504	99			
82	347704	349704	100			

\$ 2 - /) 2 ! . / , ! " 2 (9 % ! \$
 2) 3 4 % 6 , 3 5 # 3 % 7) . ' ! " 2 3 % , # (% :
 0 ! 2 4) \$! # , ! 9) 2 , % / & 2 4) % 4 (4 % \$
 # % . 4 2 % & / 2 - / , % # 5 , ! 2 % 0 2 / \$ 5 # 4
 ! . \$ % . \$ / # 2) . / , / ' 2 % 0 2 / \$ 5 (-)
 - / . ! 3 () . 3 4) 4 5 4 % / & 2 % 0 2 / \$ 5 (-)
 ! . \$ \$ % 6 % , / 0 - % . 4
 ! 2 # # % . 4 2 % / & % 8 # % ,
 ") 4 % # (. / , / ' 9 ! . \$ \$
 - % , " / 5 2 . %



\$. ! OF THESE FOUNDER MIC E
 TO DETECT THOSE CARRYING M
 h # UENTRLY EWDEOINAGR TOVEPLSTED OF PLEST E SPOMRTH ESEAL E S V
 TO % . 5 MUTAGENIZED MIC ETRIEVOEMDAOZHNRH IAVE AND USE
 4 HE ONGOING PHAETEROISATPIILOCN CAHNADR EGEATE RTHE LINE USHPNREUCTAIRVT
 LINKAGE OF LINES WITH MALE AN INFEERTILITY TECHNOLOGIESSCERSHBOVD RPR
 4 HE ESTABLISHED INQUIRY OF A S RNEOKMOUT KNOCKIN HTECHNOL
 AND ASSOCIATED OMEN O MAIND FOR . THE F REVEALDEIM ESRTIES S E
 ' MALES FOODRCTIONE OF PMRI CE 4 HE CARRYING GMENT CAFIATNH I
 MODILICATIONS IN SPENTCLYELWE O HENES " ANSERVAT#CNOY O HN
 CALLING THEVSEER GENHPIESITRO RY FERTILIZATION ACYTO&PLASMM IE
 AND IT IS BEING ESTABATIOSNH ED AS A) C O L L A B O R
 BETWEEN T4HE ! 2 E G O F # % K O E T I R L E N C E S T A B L I S H E D A E T C E N T R E S B A N I N (
 IN " I O T E C H N O L O G Y A N D \$ E V E L O P M E N T O N A S H
 5 N I S I E Y R A N D T H E E N I N G T H E Y S C B U P T O A C C O M M O D A T E
 ACCEALON IN UESTERV INTER



! 0 & 3 % 2 6) # % 3

' % . % - ! 0 0) . ' ! 4) \$.) \$ % . 4) (&) # !

4 HE ! O V A I D E B E P A C E E Q U I P M E N T E X C H A N G E A N D P E R F E R T S E A N D O M I
R U N S M A L G E O P E R T S L A C R M O A M D S O T M H A E L C C H R
L O C A T I O N A N D I D E N T I F Y T H E A F I
V A R I A N T M A D N U S O B T A I N T H R E E % F R
V A R I A N A R I E S O O B R T H E R O H E N O M E

4 HE ! O V A I D E P S R

S % X P E R T A D V A I C I N G A I N M A T E R I E N
3 . 0 S V S 3 3 , 0 S

S # A N D I D A T E ' E N E 2 E E A M Q U I N E N C
D I S C O V E R Y O F M U T A T I O N S

3 4 2 !) . # / , , % # 4) / . ! . \$

4 HE ! O V A I D E S A R F A C E S E C A N I S T R O D E D O R
A N D C H E R S E R V E R S O M E T R M I R F A R O N U S S E

4 H I S T E C H N I C I U W I N G M O D N U S S I E R S S I D E R E N H A V E A C C E S S T O T H E D A T A B
D E V E L O P E D A T S I C I N A I S A N T I C I A R V A E T O L D E C T I O N S O F M O U S E M O D I
T H O U S A N D S I N S O F M I C R O I W O L L A T A B L E T H I S H E R M A I N E I A I N G N U O L E A I
! 0 & F A C I L I T Y A N D T H E I R I N F O R M A T I O N D S E P E O R S M I T E D O N
O H E N O M E " A N K




- O U S E A I N S T H E S T I E N S C A S R W I L L B E G E N E S A N D F U N C T I O N S V I A T H E A I
T H A W E O I M T H E R E S E R V E O D P S P E R M B T A H E S A I N S A N D
C A R R I E G R E N Y P E R S T A H N V O E R T H I D Z B Y
4 H E S E C S A W R L E I B E R S H I P P E D A F T E R
E Q U E S T E S E N A G E R R R

. (- 2 # ! 5 3 4 2 ! ,) ! . 0 (%
4 H E O H E N O M E B A N K I S A N O N L I
A R C H I V E O F G E N E T I C A I N S L O F M M O I D C I
B E I N G D E V E L O P E S T A R B I N G L A T E !
I N C L U D E S A V A I L A B L E % A I N S W G I E T N H E
D A T A O N P H E A I N T B A U N K G H E I S T R R

C H O R M O S M A L L I N K A G E G E N E I D E N
O H E N O M E B A N K T O W I N C L U D E G I R I S T S
S T A R N S U S E D A A M I A N C H E S T R E S T

F2 MUTANT DNA POOLED



LINKED MARKERS
B6 homozygous

NOD

B6

F1 Mutant

3 4 2 !) . ! 6 !) , ! ") ,) 4 9

4 H E ! 0 & S G E N E F V A R I E T A S I N T H E W R H I C
H A V E E A D Y B E E N I D E N T I E D A N D S
U N I Q U E M O D E L S F O R I G N V O E S T I T Y A
A U T O I M M U N C I E T R Y A N D D E V E L O P

) N A D D I T I O N T O V E I D E S E C A R E W I C T A H N N E
S T A R N S A T A N E A R L I E R S T E A T C H E M A
L O C A T I O N E L I A M N D A R Y P H E N O T Y P E I
E S E C H E R C A N U S E T H E ! 0 & F A C I L I T



% N Q U I R I E S

! U S A T I A N O H E N O M I C S & A C I L
4 H E * O H N # U R T I N 3 C H O O L O F -
" U I L D I N G

' A E N R 2 O A D

4 H E ! A L I S A N R . A T I G S N T A Y L 5 N I V E
A N B A E R ! R # 4

4

&

% C O N T A C T A P F E D U A

W W A P F E D U A U



THE AUSTRALIAN NATIONAL UNIVERSITY